Over 1.2 million patients reachedDescription
What is Fruzaqla (fruquintinib) for?
Fruzaqla (fruquintinib) is a prescription medicine for adult patients with advanced metastatic colorectal cancer. The medicine is intended for patients who have undergone fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, where applicable, an anti-EGFR therapy.
Fruzaqla (fruquintinib) is available as capsules (1 mg and 5 mg) for oral administration.
How does Fruzaqla (fruquintinib) work?
Fruzaqla (fruquintinib) is an oral medicine that specifically acts on VEGFR -1, -2, and -3 proteins, which are crucial in the formation of blood vessels in tumors. This action helps to hinder the blood supply necessary for tumor growth.
Designed for enhanced selectivity, Fruzaqla minimizes the impact on unintended targets, enabling patients to tolerate higher doses of the medicine. It also offers the possibility of being used alongside other cancer treatments.
Where has Fruzaqla (fruquintinib) been approved?
Fruzaqla (fruquintinib) has been approved in China since 2018 under the brand name Elunate. In November 2023, Fruzaqla also received FDA approval in the USA.
The EMA is currently reviewing the marketing authorization application for Fruzaqla (fruquinitinib) within the EU
chemmedix –
Thank you uguys